Annette Hilgendorf

Partner

Dr. rer. nat., Dipl.-Biotech.

Dr. Hilgendorf joined df-mp in 2003 and is a member of the firm’s biotechnology and pharmaceuticals practice groups. She is authorized to represent clients before the German Patent and Trademark Office, the Unified Patent Court (UPC), the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

+ 49 89 210 296 0
annette.hilgendorf@df-mp.com

Annette Hilgendorf

Partner

Dr. rer. nat., Dipl.-Biotech.

Dr. Hilgendorf joined df-mp in 2003 and is a member of the firm’s biotechnology and pharmaceuticals practice groups. She is authorized to represent clients before the German Patent and Trademark Office, the Unified Patent Court (UPC), the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

+ 49 89 210 296 0
annette.hilgendorf@df-mp.com

practice areas.

As a long-standing member of the firm Dr. Hilgendorf is highly experienced in conducting opposition proceedings in the fields of pharmaceuticals, biotechnology and protein biochemistry. Dr. Hilgendorf has a scientific background in both chemistry as well as the life sciences, including molecular biology, microbial process engineering and plant biotechnology. Recently, Dr. Hilgendorf has acted as lead attorney in attacking and defending CRISPR patents in EPO opposition proceedings.

Dr. Hilgendorf is very dedicated with prosecution matters and has enforced or defended her clients’ interests in various patent disputes. A further focus of her practice is the preparation of patent infringement and validity opinions forming part of freedom-to-operate analyses in the field of medical use patents.

  

admissions.

  • German Patent Attorney
  • European Patent Attorney
  • Unified Patent Court (UPC) representative
  • European Trademark Attorney
  • European Design Attorney

AWARDS AND RECOMMENDATIONS.

  • Author of scientific papers on viral immune evasion mechanisms

curriculum vitae.

Since 2008
Since 2008

Patent att­or­ney at df-mp

2007-2008
2007-2008

Trai­nee at the Ger­man Patent Office (DPMA) and the Ger­man Fede­ral Patent Court (BPatG)

2003
2003

Joi­n­ed df-mp as a patent att­or­ney can­di­da­te

1999-2003
1999-2003

Doc­to­ra­te Degree in Bio­che­mis­try (magna cum lau­de) from the Lud­­wig-Maxi­­mi­­li­ans-Uni­­ver­­­si­­tät Mün­chen (dis­ser­ta­ti­on on the modu­la­ti­on of cel­lu­lar recep­tors upon viral infec­tion, stu­dies on the regu­la­ti­on of intracel­lu­lar pro­te­in trans­port, clo­ning of who­le ade­no­vi­rus geno­mes in bac­te­ri­al arti­fi­ci­al chro­mo­so­mes)

1999
1999

Diplô­me d’étu­des appro­fon­dies (DEA) Bio­lo­gie Molé­cu­lai­re et Cel­lu­lai­re at the Eco­le Supé­ri­eu­re de Bio­tech­no­lo­gie de Stras­bourg — Uni­ver­si­té Lou­is Pas­teur Stras­bourg, France

1996-1999
1996-1999

Degree cour­se­work (three years) in Bio­tech­no­lo­gy at the Euro­pean Con­fe­de­ra­ti­on of the Uni­ver­si­ties Basel, Frei­burg, Karls­ru­he and Stras­bourg (EUCOR) and Diplo­ma the­sis at the Uni­ver­si­ty of Michi­gan, Ann Arbor (U.S.A.) in the field of clo­ning of ade­no­vi­ral vec­tors for gene the­ra­py Diplô­me d’Ingénieur en Biotechnologie/Diplom in Bio­tech­no­lo­gie (Ger­man, French and Swiss uni­ver­si­ty degree)

1994-1996
1994-1996

Degree in Che­mis­try (Vor­di­plom Che­mie) from the Ruprecht-Karls-Uni­­ver­­­si­­tät Hei­del­berg

association memberships.

publications.

  • “Two distinct transport motifs in the adenovirus E3/10.4-14.5 proteins act in concert to down-modulate apoptosis receptors and the epidermal growth factor receptor“ A. Hilgendorf, J. Lindberg, Z. Ruszics, S. Höning, A. Elsing, M. Löfqvist, H. Engelmann, H.-G. Burgert (2003) Journal of Biological Chemistry Vol. 278, No. 51, pp. 51872-51884
  • “Immune evasion by adenovirus E3 proteins: Exploitation of intracellular trafficking pathways”. M. Windheim, A. Hilgendorf and H.-G. Burgert (2004) Review in Current Topics in Microbiology and Immunology (CTMI) 273: 30-85.
  • “Subversion of host defense mechanisms by adenoviruses” H.-G. Burgert, Z. Ruzsics, S. Obermeier, A. Hilgendorf, M. Windheim and A. Elsing (2002) Review in Current Topics in Microbiology and Immunology (CTMI) 269: 273-318.